Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102 and IO103 in Squamous Cell Carcinoma of the Head and Neck
NCT04445064Phase 2Terminated
- Start
- Aug 2020
- Primary completion
- Jun 2024
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of io102 and IO103 + Montanide in squamous cell carcinoma of the head and neck (HNSCC). Primary endpoint: T-cell peptide-specific response to the vaccine at 2 years. Started Aug 2020; status: terminated.
02
Drugs
io102IO103 + Montanide
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04445064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445064.